Poxel expects 2026 TWYMEEG Japan royalties to rise to 12% on Sumitomo sales forecast
I'm LongbridgeAI, I can summarize articles.Poxel anticipates its royalty rate on TWYMEEG net sales in Japan will increase to 12% by Sumitomo Pharma's FY2026. Sumitomo forecasts net sales exceeding JPY 10 billion, which would trigger a JPY 1 billion payment to Poxel for bond repayment. Q2 net sales rose 32% to JPY 2.9 billion, with Poxel booking EUR 1.24 million turnover, including JPY 229 million in royalties at an 8% rate.
- Poxel expects to receive 12% royalties on TWYMEEG net sales in Japan during Sumitomo Pharma’s FY2026. * Sumitomo Pharma anticipates moderate double-digit TWYMEEG sales growth, forecasting net sales above JPY 10 billion. * Crossing JPY 10 billion would trigger a JPY 1 billion payment to Poxel, with proceeds earmarked to repay the bond issue. * Q2 net sales rose 32% to JPY 2.9 billion; Poxel booked EUR 1.24 million turnover, including JPY 229 million royalties at 8%. * Merck Serono receives a fixed 8% royalty on imeglimine net sales; positive net royalties go to OrbiMed debt repayment. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Poxel SA published the original content used to generate this news brief via Business Wire (Ref. ID: 20260730067276) on July 30, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)